New alpha therapy shows promise for deadly brain cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18-80; * histologically confirmed diffuse glioma (CNS WHO G3-G4); * after standard treatment with biopsy or resection, radiotherapy and/or chemotherapy; * no sign of progression or radiation necrosis; * functional state \>70 according to Karnofsky's performance scale (KPS); * ability to give informed consent to participate in the study. Exclusion Criteria: * low-grade glioma; * progression or recurrence defined as: deterioration of the patient's condition according to the Karnofsky Performance Scale, worsening of neurological function, progressive neurological deficit, need to initiate or increase corticosteroid dose by \>50%, progression or recurrence assessed on MRI (RANO criteria); * radiation-induced necrosis secondary to radiotherapy; may occur within the first 3 months after radiotherapy (exception: a patient after resection of radiation necrosis - not earlier than 4 weeks post-surgery, after a follow-up MRI); * need for emergency surgery (e.g., acute increase in intracranial pressure); * significant postoperative complications, e.g., KPS \< 70, wound infection, cerebrospinal fluid leak; * leak into the ventricular system \>10% during the catheter patency check; * open/ventricle-connected resection cavity; * catheter obstruction; * estimated life expectancy under 3 months; * patients without preserved logical/verbal contact; * lack of cooperation from the patient; * inability to give informed, voluntary consent to participate in the study; * patients enrolled in another medical trial; * patients who received any other investigational drug within 1 month prior to the first dose; * prior treatment with \[225Ac\]Ac-DOTA-SP; * breastfeeding or pregnant women; * severe comorbid organ diseases that, in the Investigator's opinion, significantly increase the procedural risk.